Search Results - "RIOS, M. B"

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate by JABBOUR, E, KANTARJIAN, H, RIOS, M. B, VERSTOVSEK, S, CORTES, J, JONES, D, TALPAZ, M, BEKELE, N, O'BRIEN, S, ZHOU, X, LUTHRA, R, GARCIA-MANERO, G, GILES, F

“…Mutations of the BCR-ABL kinase domain are a common mechanism of resistance to imatinib in chronic myeloid leukemia. We screened for mutations 171 patients…”
Get full text

Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients by SACCHI, S, KANTARJIAN, H. M, O'BRIEN, S, CORTES, J, RIOS, M. B, GILES, F. J, BERAN, M, KOLLER, C. A, KEATING, M. J, TALPAZ, M

“…The prognoses of patients with chronic myelogenous leukemia in blastic phase (CML-BP) are extremely poor. Treatment of patients with nonlymphoid CML-BP is…”
Get full text

Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia by KANTARJIAN, H. M, O'BRIEN, S. M, KEATING, M, BERAN, M, ESTEY, E, GIRALT, S, KORNBLAU, S, RIOS, M. B, DE VOS, D, TALPAZ, M

“…The aim of the study was to evaluate the activity of decitabine, a hypomethylating agent, in the treatment of patients with chronic myelogenous leukemia (CML)…”
Get full text

Significance of cytogenetic clonal evolution in chronic myelogenous leukemia by Majlis, A, Smith, T L, Talpaz, M, O'Brien, S, Rios, M B, Kantarjian, H M

“…To describe the incidence and significance of clonal evolution patterns. We analyzed 264 patients with Philadelphia chromosome (Ph)-positive chronic…”
Get more information

Treatment of Philadelphia Chromosome-Positive Early Chronic Phase Chronic Myelogenous Leukemia With Daily Doses of Interferon Alpha and Low-Dose Cytarabine by KANTARJIAN, H. M, O'BRIEN, S, GIRALT, S, KEATING, M. J, TALPAZ, M, SMITH, T. L, RIOS, M. B, CORTES, J, BERAN, M, KOLLER, C, GILES, F. J, ANDREEFF, M, KORNBLAU, S

“…To evaluate the efficacy of the combination of interferon alpha (IFN-alpha) and daily low-dose cytarabine (ara-C) in the treatment of patients with early…”
Get full text

Periorbital Oedema and epiphora as ocular side effects of imatinib Mesylate (Gleevec) by Esmaeli, B, Diba, R, Ahmadi, M A, Saadati, H G, Faustina, M M, Shepler, T R, Talpaz, M, Fraunfelder, R, Rios, M B, Kantarjian, H

Get full text

Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia by Cortes, J, Talpaz, M, O'Brien, S, Rios, M B, Majlis, A, Keating, M, Freireich, E J, Kantarjian, H

“…To investigate whether cytogenetic clonal evolution can be suppressed with interferon alfa (IFN-alpha) therapy in patients with chronic myelogenous leukemia…”
Get more information

Determinants of prognosis in late chronic-phase chronic myelogenous leukemia by Rodriguez, J, Cortes, J, Smith, T, O'Brien, S, Rios, M B, Talpaz, M, Kantarjian, H

“…Since interferon alfa (IFN-A) became an established treatment in chronic myelogenous leukemia (CML), more patients are referred to tertiary centers in late…”
Get more information

Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization by Seong, D., Kantarjian, H.M., Albitar, M., Arlinghaus, R., Xu, J., Talpaz, M., Rios, M. B., Qiang Guo, J., O'Brien, S., Siciliano, M.

“…Background: In 5%–10% of patients with of chronic myelogenous leukemia (CML), the Philadelphia chromosome (Ph) is not identified, despite the presence of the…”
Get full text

Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy by Kantarjian, H M, Talpaz, M, Hester, J, Feldman, E, Korbling, M, Liang, J, Rios, M B, Smith, T L, Calvert, L, Deisseroth, A B

“…To evaluate whether intensive chemotherapy followed by peripheral stem-cell (PSC) collections during early hematopoietic recovery results in a higher…”
Get more information

Phase I Study of Topotecan, A New Topoisomerase I Inhibitor, in Patients With Refractory or Relapsed Acute Leukemia by Kantarjian, Hagop M., Beran, Miloslav, Ellis, Amy, Zwelling, Leonard, O'Brien, Susan, Cazenave, Lorraine, Koller, Charles, Rios, Mary Beth, Plunkett, William, Keating, Michael J., Estey, Elihu H.

“…The purpose of this study was to define, in a phase I study in leukemia, the maximally tolerated dose (MTD), major toxicities, and possible antitumor activity…”
Get full text

Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study by BERAN, M, JEHA, S, O'BRIEN, S, ESTEY, E, VITEK, L, ZURLO, M. G, RIOS, M. B, KEATING, M, KANTARJIAN, H

“…Despite progress in leukemia therapy, only 20-30% of patients with acute myelogenous leukemia (AML) are cured. 1-beta-D-arabinofuranosylcytosine- and…”
Get full text

The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia by KOLLER, C. A, KANTARJIAN, H. M, THOMAS, D, O'BRIEN, S, RIOS, M. B, KORNBLAU, S, MURPHY, S, KEATING, M

Get full text

Decitabine studies in chronic and acute myelogenous leukemia by KANTARJIAN, H. M, O'BRIEN, S. M, ESTEY, E, GIRALT, S, BERAN, M, RIOS, M. B, KEATING, M, DE VOS, D, TALPAZ, M

Get full text

Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor by Kantarjian, H M, Talpaz, M, Kontoyiannis, D, Gutterman, J, Keating, M J, Estey, E H, O'Brien, S, Rios, M B, Beran, M, Deisseroth, A

“…The study was undertaken to improve the results of intensive chemotherapy in chronic myelogenous leukemia (CML) in accelerated (CML-AP) and blastic phases…”
Get more information

Unravelling the structure of cucurbitoid teeth in the Cucurbitaceae by Gonçalves, Jailma R., Rios, Alex B. M., Dalvi, Valdnéa C.

“…Leaf teeth, i.e. projections of the leaf margin, are common among angiosperms. These structures may differ in several aspects, e.g. in the presence or absence…”
Get full text

Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results by Cortes, J E, Talpaz, M, Beran, M, O'Brien, S M, Rios, M B, Stass, S, Kantarjian, H M

“…Five to 10% of patients with chronic myelogenous leukemia (CML) do not have the Philadelphia chromosome (Ph), but one-third of them have rearrangements of the…”
Get more information

Serum β-2 Microglobulin Levels Are a Significant Prognostic Factor in Philadelphia Chromosome-positive Chronic Myelogenous Leukemia by RODRIGUEZ, J, CORTES, J, TALPAZ, M, O'BRIEN, S, SMITH, T. L, RIOS, M. B, KANTARJIAN, H

“…Our objective was to investigate the prognostic significance of serum β-2 microglobulin (B2M) levels among patients with chronic myelogenous leukemia (CML)…”
Get full text

Chromosomal abnormalities in Philadelphia chromosome‐negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome‐positive chronic myelogenous leukemia in chronic phase by Medina, Jorge, Kantarjian, Hagop, Talpaz, Moshe, O'Brien, Susan, Garcia‐Manero, Guillermo, Giles, Francis, Rios, Mary Beth, Hayes, Kimberly, Cortes, Jorge

“…BACKGROUND Anecdotal cases of chromosomal abnormalities in Philadelphia chromosome (Ph)‐negative metaphases have been reported in patients with chronic…”
Get full text

A Phase I–II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia by Koller, Charles A., Kantarjian, Hagop M., Feldman, Eric J., O'Brien, Susan, Rios, Mary Beth, Estey, Elihu, Keating, Michael

“…BACKGROUND Cytarabine is an essential drug for inducing remission of acute myelogenous leukemia, and it is also one the most effective drugs used as salvage…”
Get full text